Description:
Eliglustat hemitartrate is a specific inhibitor of glucosylceramide synthase. It is under development as an oral substrate reduction therapy for Gaucher disease type 1 (GD1). It was developed by Genzyme Corp and has been listed by the FDA August 2014.
- Molecular Weight: 959.17
- Molecular Formula: C50H78N4O14
Purity: >98%
Canonical SMILES:
CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O.CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O.C(C(C(=O)O)O)(C(=O)O)O
InChI:
InChI=1S/2C23H36N2O4.C4H6O6/c2*1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20;5-1(3(7)8)2(6)4(9)10/h2*10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26);1-2,5-6H,(H,7,8)(H,9,10)/t2*19-,23-;1-,2-/m111/s1
InChIKey: KUBARPMUNHKBIQ-VTHUDJRQSA-N
- Solubility: 10 mM in DMSO
- Appearance: Solid powder
- Storage: -20°C Freezer
Synonyms:
Genz-112638; Genz 112638; Genz112638; Eliglustat tartrate; Bis(N-((1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(pyrrolidin-1- ylmethyl)ethyl)octanamide) (2R,3R)-2,3-dihydroxybutanedioate; Octanamide, N-((1R,2R)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1- pyrrolidinylmethyl)ethyl)-, (2R,3R)-2,3-dihydroxybutanedioate; N-[(1R,2R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-pyrrolidin-1-ylpropan-2-yl]octanamide (2R,3R)-2,3-dihydroxybutanedioic acid
More details are to be found on supplier website
